You are here: Industry Insights > Harbour BioMed

News List

Harbour BioMed, PPD partner for oncology and immunology biospectrumasia
August 28, 2019
Harbour BioMed and PPD Form Strategic Collaboration to Develop Innovative Therapeutics for Oncology and Immunology
Harbour BioMed, CTTQ unite to discover, develop and commercialize Innovative Biologics biospectrumasia
May 06, 2019
Global collaboration focused on new antibody treatments in the fields of oncology and immunology
Harbour BioMed announces partnership with Kelun-Biotech biospectrumasia
August 22, 2018
The companies will also collaborate in developing combination therapies of A167 with other agents for commercialization in their respective territories.
Harbour BioMed, Kelun-Biotech Enter Agreement fiercebiotech
August 22, 2018
Harbour BioMed has entered into an exclusive strategic partnership with Kelun-Biotech to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.
China’s Harbour BioMed, Kelun ink a PD-L1 deal worth up to $350M fiercebiotech
August 21, 2018
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China. Kelun stands to earn up to $350 million, but the partners did not specify how much the deal was worth upfront.
Glenmark signs licence deal with Harbour BioMed biospectrumasia
August 08, 2018
Exclusive license agreement potentially worth more than $120 million in addition to royalties
Harbour BioMed to develop and commercialise HanAll’s biologic therapies in Greater China pharmaceufical-technology
September 14, 2017
The deal includes HanAll Biopharma’s anti-Fc receptor (FcRn) monoclonal antibody, HL161, and anti-tumour necrosis factor (TNF) ophthalmic solution, HL036.
HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Bi prnasia
September 12, 2017
HanAll Biopharma Co., Ltd. (009420.KS) and Harbour BioMed announced today that they have entered into a strategic collaboration and license agreement to develop

Previous page 1 2 Next page